Guilin Sanjin Pharmaceutical Co., Ltd. (SHE:002275)
China
· Delayed Price · Currency is CNY 14.23
+0.28 (2.01%)
Apr 29, 2026, 3:04 PM CST
SHE:002275 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 2,046 | 2,192 | 2,168 | 1,954 | 1,739 | Upgrade
|
| Other Revenue | - | 1.76 | 3.66 | 5.27 | 2.71 | Upgrade
|
| Revenue | 2,046 | 2,194 | 2,172 | 1,960 | 1,741 | Upgrade
|
| Revenue Growth (YoY) | -6.76% | 1.03% | 10.81% | 12.55% | 11.15% | Upgrade
|
| Cost of Revenue | 490.41 | 610.47 | 602.57 | 574.37 | 457.04 | Upgrade
|
| Gross Profit | 1,555 | 1,584 | 1,569 | 1,385 | 1,284 | Upgrade
|
| Selling, General & Admin | 817.78 | 888.26 | 920.66 | 812.68 | 722.13 | Upgrade
|
| Research & Development | 160.04 | 173.29 | 158.06 | 217.04 | 201.6 | Upgrade
|
| Other Operating Expenses | 9.36 | 32.28 | 29.89 | 36.09 | 32.8 | Upgrade
|
| Operating Expenses | 987.18 | 1,103 | 1,109 | 1,070 | 957.81 | Upgrade
|
| Operating Income | 568.15 | 480.47 | 460.41 | 315.65 | 326.37 | Upgrade
|
| Interest Expense | - | -13.84 | -16.36 | -20.24 | -18.21 | Upgrade
|
| Interest & Investment Income | 5.25 | 34.4 | 33.17 | 40.64 | 39.8 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.19 | -0.08 | -3.59 | 0.57 | Upgrade
|
| Other Non Operating Income (Expenses) | -26.17 | -0.25 | 0.05 | -0.58 | -1.23 | Upgrade
|
| EBT Excluding Unusual Items | 547.22 | 500.97 | 477.2 | 331.89 | 347.31 | Upgrade
|
| Gain (Loss) on Sale of Investments | 7.71 | 4.65 | 1.19 | 0.16 | 1.77 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.15 | 83.36 | 1.67 | 31.26 | 15.5 | Upgrade
|
| Asset Writedown | -18.16 | -0.86 | -0.17 | -1.02 | -8.12 | Upgrade
|
| Other Unusual Items | - | 55.82 | 38.39 | 83.89 | 72.61 | Upgrade
|
| Pretax Income | 536.93 | 643.93 | 518.28 | 446.18 | 429.06 | Upgrade
|
| Income Tax Expense | 103.79 | 122.4 | 96.99 | 116.65 | 85.34 | Upgrade
|
| Net Income | 433.13 | 521.53 | 421.3 | 329.53 | 343.72 | Upgrade
|
| Net Income to Common | 433.13 | 521.53 | 421.3 | 329.53 | 343.72 | Upgrade
|
| Net Income Growth | -16.95% | 23.79% | 27.85% | -4.13% | 24.08% | Upgrade
|
| Shares Outstanding (Basic) | 585 | 586 | 585 | 588 | 573 | Upgrade
|
| Shares Outstanding (Diluted) | 585 | 586 | 585 | 588 | 573 | Upgrade
|
| Shares Change (YoY) | -0.11% | 0.15% | -0.56% | 2.72% | -0.74% | Upgrade
|
| EPS (Basic) | 0.74 | 0.89 | 0.72 | 0.56 | 0.60 | Upgrade
|
| EPS (Diluted) | 0.74 | 0.89 | 0.72 | 0.56 | 0.60 | Upgrade
|
| EPS Growth | -16.85% | 23.61% | 28.57% | -6.67% | 25.00% | Upgrade
|
| Free Cash Flow | 621.18 | 506.16 | 472.85 | 466.4 | 266.15 | Upgrade
|
| Free Cash Flow Per Share | 1.06 | 0.86 | 0.81 | 0.79 | 0.47 | Upgrade
|
| Dividend Per Share | - | 0.600 | 0.600 | 0.800 | 0.900 | Upgrade
|
| Dividend Growth | - | - | -25.00% | -11.11% | 125.00% | Upgrade
|
| Gross Margin | 76.03% | 72.17% | 72.25% | 70.69% | 73.75% | Upgrade
|
| Operating Margin | 27.77% | 21.90% | 21.20% | 16.11% | 18.74% | Upgrade
|
| Profit Margin | 21.17% | 23.77% | 19.40% | 16.81% | 19.74% | Upgrade
|
| Free Cash Flow Margin | 30.36% | 23.07% | 21.77% | 23.80% | 15.29% | Upgrade
|
| EBITDA | 654.91 | 571.42 | 575.53 | 412.21 | 412.97 | Upgrade
|
| EBITDA Margin | 32.01% | 26.05% | 26.50% | 21.03% | 23.72% | Upgrade
|
| D&A For EBITDA | 86.76 | 90.95 | 115.12 | 96.55 | 86.6 | Upgrade
|
| EBIT | 568.15 | 480.47 | 460.41 | 315.65 | 326.37 | Upgrade
|
| EBIT Margin | 27.77% | 21.90% | 21.20% | 16.11% | 18.74% | Upgrade
|
| Effective Tax Rate | 19.33% | 19.01% | 18.71% | 26.15% | 19.89% | Upgrade
|
| Revenue as Reported | - | 2,194 | 2,172 | 1,960 | 1,741 | Upgrade
|
| Advertising Expenses | - | 530.36 | 514.72 | 361.86 | 378.93 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.